| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.
|
Schizophr Res
|
2008
|
5.99
|
|
2
|
Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.
|
Schizophr Res
|
2011
|
5.39
|
|
3
|
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
|
Schizophr Res
|
2005
|
5.31
|
|
4
|
Schizophrenia, "just the facts" 4. Clinical features and conceptualization.
|
Schizophr Res
|
2009
|
3.68
|
|
5
|
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
|
Schizophr Res
|
2005
|
2.91
|
|
6
|
Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology.
|
Schizophr Res
|
2008
|
2.67
|
|
7
|
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
|
J Clin Psychiatry
|
2002
|
2.57
|
|
8
|
Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future.
|
Schizophr Res
|
2010
|
2.47
|
|
9
|
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
|
Schizophr Res
|
2008
|
1.97
|
|
10
|
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
|
Schizophr Res
|
2008
|
1.95
|
|
11
|
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
|
J Clin Psychiatry
|
2015
|
1.73
|
|
12
|
Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview.
|
Schizophr Res
|
2008
|
1.71
|
|
13
|
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
|
Schizophr Res
|
2008
|
1.37
|
|
14
|
The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
|
J Clin Psychopharmacol
|
2004
|
1.35
|
|
15
|
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
|
Schizophr Res
|
2005
|
1.28
|
|
16
|
"Just the facts": meandering in schizophrenia's many forests.
|
Schizophr Res
|
2011
|
1.18
|
|
17
|
Pain insensitivity in schizophrenia: trait or state marker?
|
J Psychiatr Pract
|
2006
|
1.11
|
|
18
|
Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats.
|
J Pharmacol Exp Ther
|
2006
|
1.01
|
|
19
|
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
|
Ann Clin Psychiatry
|
2006
|
1.00
|
|
20
|
Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.
|
Rev Recent Clin Trials
|
2012
|
0.95
|
|
21
|
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
|
J Affect Disord
|
2004
|
0.94
|
|
22
|
Impaired plasmalogens in patients with schizophrenia.
|
Psychiatry Res
|
2012
|
0.93
|
|
23
|
Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
|
J Clin Psychopharmacol
|
2003
|
0.93
|
|
24
|
Strategies for maximizing clinical effectiveness in the treatment of schizophrenia.
|
J Psychiatr Pract
|
2006
|
0.93
|
|
25
|
On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.
|
Expert Opin Pharmacother
|
2011
|
0.91
|
|
26
|
Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics.
|
PLoS One
|
2013
|
0.91
|
|
27
|
An analysis of the high psychotropic off-label use in psychiatric disorders The majority of psychiatric diagnoses have no approved drug.
|
Asian J Psychiatr
|
2009
|
0.90
|
|
28
|
Neurological disorders in schizophrenia.
|
Psychiatr Clin North Am
|
2009
|
0.89
|
|
29
|
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
|
Biol Psychiatry
|
2009
|
0.87
|
|
30
|
Hippocampal dysfunction in Gulf War Syndrome. A proton MR spectroscopy study.
|
Brain Res
|
2004
|
0.87
|
|
31
|
Schizophrenia and aging: no more dearth of data?
|
Am J Geriatr Psychiatry
|
2003
|
0.84
|
|
32
|
Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.
|
Front Psychiatry
|
2012
|
0.83
|
|
33
|
Single-voxel proton MR spectroscopy of right versus left hippocampi in PTSD.
|
Psychiatry Res
|
2003
|
0.82
|
|
34
|
Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure.
|
Schizophr Bull
|
2012
|
0.82
|
|
35
|
CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.
|
Schizophr Res
|
2013
|
0.81
|
|
36
|
The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy.
|
Ann Clin Psychiatry
|
2006
|
0.81
|
|
37
|
Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.
|
Schizophr Res
|
2007
|
0.80
|
|
38
|
Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.
|
J Clin Psychiatry
|
2004
|
0.80
|
|
39
|
Perspectives on the Positive and Negative Syndrome Scale (PANSS): Use, misuse, drawbacks, and a new alternative for schizophrenia research.
|
Ann Clin Psychiatry
|
2016
|
0.79
|
|
40
|
Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
|
Arch Gen Psychiatry
|
2006
|
0.79
|
|
41
|
Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy.
|
J Psychopharmacol
|
2006
|
0.79
|
|
42
|
Antipsychotic drugs.
|
Handb Clin Neurol
|
2012
|
0.79
|
|
43
|
Paliperidone: a new extended-release oral atypical antipsychotic.
|
Expert Opin Pharmacother
|
2007
|
0.79
|
|
44
|
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.
|
Int Clin Psychopharmacol
|
2016
|
0.79
|
|
45
|
Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder.
|
Psychopharmacol Bull
|
2006
|
0.78
|
|
46
|
Linkage of cognitive impairments with metabolic disorders in schizophrenia.
|
Am J Psychiatry
|
2010
|
0.78
|
|
47
|
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
|
Schizophr Res
|
2013
|
0.77
|
|
48
|
Risperidone in the treatment of delirium: results from a prospective open-label trial.
|
J Clin Psychiatry
|
2004
|
0.77
|
|
49
|
Pathological laughter and crying: A case series and proposal for a new classification.
|
Ann Clin Psychiatry
|
2016
|
0.77
|
|
50
|
Temporal sequence of clinical manifestation in schizophrenia with co-morbid OCD: review and meta-analysis.
|
Psychiatry Res
|
2008
|
0.77
|
|
51
|
Improving the pedagogy associated with the teaching of psychopharmacology.
|
Acad Psychiatry
|
2007
|
0.76
|
|
52
|
Executive function impairment in first-degree relatives of persons with schizophrenia: A meta-analysis of controlled studies.
|
Asian J Psychiatr
|
2011
|
0.76
|
|
53
|
NMDA receptor antagonists for depression: Critical considerations.
|
Ann Clin Psychiatry
|
2015
|
0.76
|
|
54
|
A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
|
Ann Clin Psychiatry
|
2015
|
0.76
|
|
55
|
Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations.
|
CNS Spectr
|
2008
|
0.75
|
|
56
|
Schizophrenia and obsessive-compulsive disorder.
|
Am J Psychiatry
|
2010
|
0.75
|
|
57
|
Treatment of bipolar disorder.
|
J Clin Psychiatry
|
2003
|
0.75
|
|
58
|
Does the neurotoxicity of haloperidol explain the higher mortality in dementia patients compared with the second generation agents?
|
Am J Psychiatry
|
2012
|
0.75
|
|
59
|
25 years of editing Schizophrenia research: a unique and gratifying journey.
|
Schizophr Res
|
2012
|
0.75
|
|
60
|
Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia.
|
Ann Clin Psychiatry
|
2015
|
0.75
|
|
61
|
Celebrating twenty years of schizophrenia research.
|
Schizophr Res
|
2008
|
0.75
|
|
62
|
A Valedictory from the Founding Editors.
|
Schizophr Res
|
2016
|
0.75
|
|
63
|
The intense desire for healthy limb amputation: A dis-proprioceptive neuropsychiatric disorder.
|
Ann Clin Psychiatry
|
2017
|
0.75
|
|
64
|
Psychiatric and physical comorbidity in schizophrenia. Preface.
|
Psychiatr Clin North Am
|
2009
|
0.75
|
|
65
|
Meta-analysis trends in schizophrenia over three decades.
|
Schizophr Res
|
2009
|
0.75
|
|
66
|
Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.
|
Ann Clin Psychiatry
|
2016
|
0.75
|